In high-risk type 2 diabetes, adding oral semaglutide to standard care reduced MACE at a mean 48 mo.
Where this comes from
- Record sourced from PubMed, PMID 40587855.
- Also identified by DOI 10.7326/ANNALS-25-02173-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
GIM/FP/GP: [Formula: see text] Cardiology: [Formula: see text] Endocrinology: [Formula: see text] Nephrology: [Formula: see text].
Medical subject headings
- Diabetes Mellitus, Type 2
- Glucagon-Like Peptides
- Hypoglycemic Agents
- Cardiovascular Diseases